VIVS - ORGANOVO HOLDINGS, INC.

1.83
-0.050   -2.732%

Share volume: 28,994
Last Updated: 03-06-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: 0.17%

PREVIOUS CLOSE
CHG
CHG%
$1.88
-0.05
-0.03%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
9%
Profitability 8%
Dept financing 2%
Liquidity 58%
Performance 0%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-4.69%
1 Month
-6.15%
3 Months
-23.43%
6 Months
-26.51%
1 Year
346.34%
2 Year
79.41%
Key data
Stock price
$1.83
P/E Ratio 
0.00
DAY RANGE
$1.82 - $1.89
EPS 
$3.21
52 WEEK RANGE
$0.25 - $5.30
52 WEEK CHANGE
$346.34
MARKET CAP 
3.822 M
YIELD 
N/A
SHARES OUTSTANDING 
2.600 M
DIVIDEND
$0.00
EX-DIVIDEND DATE
03-21-2025
NEXT EARNINGS DATE
05-30-2025
BETA 
-0.10
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$104,131
AVERAGE 30 VOLUME 
$120,999
Company detail
CEO: Keith Murphy
Region: US
Website: organovo.com
Employees: 20
IPO year: 2012
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

Organovo Holdings, Inc. focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells. The company is developing in vivo liver tissues to treat end-stage liver, life-threatening, and orphan diseases.

Recent news